New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 15, 2013
07:15 EDTPCYCPharmacyclics price target raised to $96 from $83 at Piper Jaffray
Piper Jaffray said Pharmacyclics confirmed the filing for ibrutinib in Mantle Cell Lymphoma, or MCL, by year end, which places the launch one year ahead of Street expectations. The firm raised its price target for shares and keeps an Overweight rating on the name.
News For PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 25, 2014
16:02 EDTPCYCPharmacyclics, Server agree to end pan-HDAC inhibitor collaboration
Pharmacyclics and Servier announced that they have mutually and amicably ended their collaboration pertaining to the ex-U.S. development of Pharmacyclics' pan-HDAC inhibitor compounds involving abexinostat, thereby returning global development and commercialization rights to Pharmacyclics. A provisional patent application for abexinostat tosylate was filed with the U.S. Patent and Trademark Office in 2013 and, if issued, would extend patent protection until 2034. Pharmacyclics will evaluate the full opportunity that the compound may afford, and plans to provide an update on this program in mid 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use